• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
cnb1439_3rs-project_nav-ad_v1
  • About us
  • News
  • Events
  • Careers
cn-bio-organ-on-a-chip-logo
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Gut/Liver-on-a-chip
    • Lung-on-a-chip
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Technology
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers in Biotech
  • Contact us

Explore our solutions


PhysioMimix® is a suite of hardware, consumables and assay protocols that enable you to recreate complex human biology and accurately predict human drug responses.

PhysioMimix OOC

physiomimix-single-and-multi-organ-on-a-chip-systems
Learn more

Consumables

Multi-chip plates
3D validated cells
NASH-in-a-box
Bioavailability assay kit: Human 18
DILI assay kit: Human 24
Learn more

Models

Single-organ models
- Liver-on-a-chip model
- Lung-on-a-chip model
Multi-organ models
- Gut/Liver-on-a-chip models

Support packages

PhysioMimix® support packages

Discover the applications


Investigate the application areas that our PhysioMimix® products and services support

Learn more

Disease modeling

Metabolic dysfunction-associated steatohepatitis
Hepatitis B
Pulmonary infection
Learn more

Safety toxicology

Drug-induced liver injury
Immune-mediated liver injury
Learn more

ADME

Drug absorption
Drug metabolism
Drug bioavailability
Oligonucleotide delivery
Learn more

Studies as a service


Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

Learn more
icon-nash-1-150x150.png MASLD/MASH
icon-dili-tox-150x150.png Drug-induced liver injury
icon-adme-150x150.png ADME

CN Bio and Cambridge University identify novel regulatory pathway driving NASH

June 9, 2020

  • Paper published in Nature Metabolism demonstrates novel pathway regulating the underlying mechanism of liver fibrosis 
  • Research harnesses CN Bio’s liver-on-chip NASH disease model, to advance development of potential new medicines for liver fibrosis 

CN Bio, a leading cell culture company that has developed single and multi-organ microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, today announced the publication of co-authored research led by researchers at the University of Cambridge in Nature Metabolism1, identifying a novel pathway that regulates the underlying mechanism of Non-Alcoholic Steatohepatitis (NASH), potentially a new therapeutic target. The collaborative work uses CN Bio’s NASH model to help elucidate the complex cellular mechanisms that cause liver fibrosis. 

The group demonstrated that Bone Morphogenetic Protein 8B (BMP8B), a poorly characterised member of the BMP/TGFβ superfamily, exhibits marked upregulation during Non-Alcoholic Fatty Liver Disease (NAFLD) to NASH disease progression. This surge of BMP8B was shown to be an important mediator of liver disease progression, and a leading pathogenic mediator of the wound healing response of NASH, therefore presenting itself as a potential therapeutic target.  

Contributing organisations include: University of Cambridge, Newcastle University, National & Kapodistrian University of Athens, Nordic Bioscience A/S, Sorbonne Université, Imperial College London and Wellcome Trust Sanger Institute 

The paper illustrates the direct translation between CN Bio’s NASH assay, human clinical studies and in vivo mouse models. It demonstrates that the MPS NASH model can offer more human-relevant data than standard liver tissue studies, and a quicker and cheaper option to study NASH pathophysiology with similar results to long and expensive animal models to better inform the drug discovery process and reduce associated costs. Cell cultures were performed in CN Bio’s MPS NASH model, utilising its proprietary liver-on-chip technology, which enables longer term in vitro culture (>1 month) of primary human hepatocytes in 3D microtissue structures. The NASH assay captures all key aspects of the different stages of the NAFLD/NASH spectrum: intracellular fat accumulation, inflammation and fibrosis.  

Dr David Hughes, CEO, CN Bio, commented: “Increasing global levels of obesity are paralleled with growing numbers of NASH patients. However, currently there are no therapies on the market to treat the disease, with candidates in phase 3 clinical trials not effective enough to treat the majority of patients. By providing human-relevant organ-on-chip data, our NASH model is enabling researchers to screen new NAFLD and NASH therapeutic candidates, investigate mechanisms of action and generate actionable data in weeks, ultimately to fast-track investigation into new drug candidates.”  

Dr Tomasz Kostrzewski, Director, Biology, CN Bio, said: “This paper demonstrates how industry leaders in fatty liver disease, NASH and fibrosis have recognised the quality of CN Bio’s research and the reliability of our data. We’re excited to see this research published in Nature Metabolism, a new and exciting journal for our field which will become highly impactful.” 

  1. ‘Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis’, Nature Metabolism, https://www.nature.com/articles/s42255-020-0214-9  

CN Bio’s NASH model is available as a fee-for-service offering, performed and analysed using the Company’s PhysioMimix™ MPS. The offering supports researchers in planning and optimising clinical trial design, to prioritise pre-clinical candidates and integrate effects on different target cell types of the liver.  

For more information about CN Bio’s NASH drug discovery fee-for-service, please visit: https://cn-bio.com/nash-fee-for-service/  

Category iconPress releases

Primary Sidebar

Other recent news

  • Integrating In Silico Tools with Organ-on-a-Chip to advance ADME studies July 15, 2025
  • NIH to prioritize human-based research technologies & reduce animal use in research July 7, 2025
  • CN Bio to participate in 3Rs Collaborative-lead project with FDA to build confidence in Liver MPS for DILI June 25, 2025
  • CN Bio introduces cross-species DILI services to enhance in vitro to in vivo extrapolation during preclinical drug development June 10, 2025
  • CN Bio expands access to OOC solutions for APAC customers with distributor agreement in South Korea May 20, 2025

Speak to our experts

Request a meeting with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Regulatory | Accessibility
Website terms | Terms of sale

Product Recycling

©2025 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • Integrating In Silico Tools with Organ-on-a-Chip to advance ADME studies July 15, 2025
  • NIH to prioritize human-based research technologies & reduce animal use in research July 7, 2025
  • CN Bio to participate in 3Rs Collaborative-lead project with FDA to build confidence in Liver MPS for DILI June 25, 2025
Cyber Essentials Logo